XNAS · Healthcare · Biotechnology
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q3 2026 | — | -0.66 | — | $0 | — | +1.60% | -5.08% | — |
| 2026-02-17 | Q2 2026 | — | -0.82 | — | $0 | — | +0.00% | +0.91% | +6.36% |
| 2025-11-17 | Q1 2026 |
| — |
| -0.12 |
| — |
| $0 |
| — |
| — |
| — |
| — |
| 2025-09-26 | Q4 2025 | — | -0.40 | — | $0 | — | — | — | — |
Showing last 4 quarters.